| Literature DB >> 31881849 |
Jing Jiang1, Qiu-Li Liang1, Li-Hua Liu1, Shuang-Qi Cai1, Zhong-Ye Du1, Jin-Liang Kong2, Yi-Qiang Chen3.
Abstract
BACKGROUND: To investigate the clinical features of septic pulmonary embolism (SPE) cases and prognostic factors for in-hospital mortality in China.Entities:
Keywords: Bacteremia; Lung abscess; Septic pulmonary embolism
Mesh:
Substances:
Year: 2019 PMID: 31881849 PMCID: PMC6935238 DOI: 10.1186/s12879-019-4672-1
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Baseline characteristics, univariate analysis and Logistic regression analysis of prognostic factors for in-hospital mortality of the 98 patients with SPE
| Characteristics/Variables | No. (%)/Value | Survival | Death | univariate analysis | Logistic regression | ||
|---|---|---|---|---|---|---|---|
| ( | ( | P | P | OR | 95% CI | ||
| Age (years) | 46.6 ± 15.2 | 44.4 ± 14.0 | 56.0 ± 16.8 | 0.002 | 0.002 | 1.100 | 1.035–1.169 |
| Sex (male/female) | 81/17 | 66/13 | 15/4 | 0.635 | |||
| Smoking history | 43 (43.9%) | 34 | 9 | 0.733 | |||
| Presenting symptoms, n (%) | |||||||
| 2003Fever (> 38 °C) | 70(71.4%) | 56 | 14 | 0.808 | |||
| Cough | 52(53.1%) | 41 | 11 | 0.638 | |||
| Weight loss | 27(27.6%) | 19 | 8 | 0.114 | |||
| Dyspnea | 23(23.5%) | 16 | 7 | 0.126 | |||
| Chest pain | 17(17.3%) | 12 | 5 | 0.250 | |||
| Vital sign | |||||||
| Hypotension (SBP < 90 mmHg) | 13(13.3%) | 6 | 7 | 0.001 | 0.037 | 7.260 | 1.126–46.804 |
| Heart rate (> 100/min) | 28(28.6%) | 22 | 6 | 0.747 | |||
| Respiratory rate (> 22/min) | 25(25.5%) | 18 | 7 | 0.207 | |||
| Comorbidities | |||||||
| Diabetes mellitus | 41(41.8%) | 33 | 8 | 0.979 | |||
| Heart disease | 17(17.3%) | 12 | 5 | 0.250 | |||
| Chronic liver disease (cirrhosis, hepatitis) | 12(12.2%) | 9 | 3 | 0.892 | |||
| Chronic kidney disease | 11(11.2%) | 7 | 4 | 0.268 | |||
| COPD | 10(10.2%) | 7 | 3 | 0.636 | |||
| Venous thromboembolism | 9(9.2%) | 8 | 1 | 0.828 | |||
| Deep vein thrombosis | 6(6.1%) | 6 | 0 | 0.593 | |||
| Pulmonary embolism | 3(3.1%) | 2 | 1 | 1.000 | |||
| Malignancy | 5(5.1%) | 4 | 1 | 1.000 | |||
| Collagen vascular disease or other autoimmune disorders | 5(5.1%) | 5 | 0 | 0.263 | |||
| Cerebrovascular disease | 4(4.1%) | 4 | 0 | 0.319 | |||
| Predisposing conditions | |||||||
| Nosocomial infection | 21(21.4%) | 14 | 7 | 0.035 | 0.231 | 2.647 | 0.538–13.015 |
| IV drug use | 18(18.4%) | 12 | 6 | 0.098 | |||
| Immunosuppressed state | 16(16.3%) | 12 | 4 | 0.783 | |||
| Venous catheter insertion | 13(13.3%) | 8 | 5 | 0.136 | |||
| Injury or other trauma | 12(12.2%) | 9 | 3 | 0.892 | |||
| Infectious foci | |||||||
| Skin and other soft tissue infection | 30(30.6%) | 23 | 7 | 0.512 | |||
| Infective endocarditis | 20(20.4%) | 15 | 5 | 0.477 | |||
| Liver abscess | 17(14.3%) | 14 | 3 | 1.000 | |||
| Catheter-associated blood stream infection | 9(9.2%) | 6 | 3 | 0.504 | |||
| Urinary tract infection | 6(6.1%) | 5 | 1 | 1.000 | |||
| Perianal abscess | 5(5.1%) | 4 | 1 | 1.000 | |||
| Cholecystitis or cholangitis | 3(3.1%) | 3 | 0 | 1.000 | |||
| Infectious endophthalmitis | 2(2.0%) | 1 | 1 | 0.839 | |||
| Peritonsillar abscess | 1(1.0%) | 0 | 1 | 0.194 | |||
| Periodontal abscess | 1(1.0%) | 1 | 0 | 1.000 | |||
| Meningitis | 1(1.0%) | 0 | 1 | 0.194 | |||
| Unknown | 3(3.1%) | 3 | 0 | 1.000 | |||
| Laboratory data | |||||||
| WBC count (×109/L) | 15.9 ± 7.3 | 15.9 ± 8.0 | 15.5 ± 2.9 | 0.818 | |||
| Neutrophil ratio | 0.8 ± 0.1 | 0.8 ± 0.1 | 0.8 ± 0.2 | 0.873 | |||
| ESR, mm/hr | 64.6 ± 30.2 | 63.7 ± 28.5 | 68.4 ± 36.8 | 0.547 | |||
| Serum CRP (mg/L) | 84.0(55.9–135.0) | 104.9 ± 63.1 | 89.5 ± 62.9 | 0.343 | |||
| Serum PCT (ng/ml) | 1.36(0.29–6.52) | 4.22 ± 2.18 | 5.74 ± 3.39 | 0.242 | |||
| PO2 (< 60 mmHg) | 19(19.4%) | 14 | 5 | 0.395 | |||
| Lactate level (> 2.0/mmol/L) | 8(8.2%) | 4 | 4 | 0.069 | |||
| Gram-positive organisms of blood culture | 19(21.4%) | 13 | 6 | 0.134 | |||
| Gram-negative organisms of blood culture | 11(21.4%) | 7 | 4 | 0.268 | |||
| Candidemia | 3(21.4%) | 0 | 3 | < 0.001 | |||
| Deep fungal infection | 14(14.3%) | 8 | 6 | 0.016 | 0.233 | 0.193 | 0.013–2.885 |
| MDRP infection | 19(19.4%) | 11 | 8 | 0.005 | 0.089 | 5.999 | 0.763–47.152 |
| Clinical Course and complication | |||||||
| Ineffective or delayed EAT | 24(24.5%) | 15 | 9 | 0.023 | 0.035 | 7.341 | 1.145–47.045 |
| Drainage treatment | 26(26.5%) | 25 | 1 | 0.040 | 0.027 | 0.330 | 0.002–0.677 |
| Respiratory failure | 19(19.4%) | 12 | 7 | 0.032 | 0.064 | 6.663 | 0.898–49.462 |
| Heart failure | 20(20.4%) | 14 | 6 | 0.178 | |||
| Renal failure | 14(14.3%) | 9 | 5 | 0.095 | |||
| Liver insufficiency | 10(10.2%) | 7 | 3 | 0.636 | |||
| Coagulation disorders | 4(4.1%) | 1 | 3 | 0.026 | |||
| MODS | 21(21.4%) | 13 | 8 | 0.014 | 0.866 | 1.147 | 0.234–5.629 |
| Duration of hospitalization, days | 22.7 ± 11.1 | 21.4 ± 10.5 | 27.6 ± 13.8 | 0.037 | 0.895 | 1.005 | 0.935–1.080 |
Abbreviations: SBP Systolic blood pressure, COPD Chronic obstructive pulmonary disease, IV Intravenous, WBC white blood cell, ESR Erythrocyte sedimentation rate, CRP C reactive protein, PCT Procalcitonin, PO: Partial pressure of oxygen, EAT Empirical antimicrobial therapy, MODS Multiple organ dysfunction syndrome
Microorganisms isolated from patients with SPE
| Pathogens | Blood | Sputum | Pus | Urine | BALF | Pleural effusion | Total |
|---|---|---|---|---|---|---|---|
| ( | ( | ( | ( | ( | ( | ( | |
| Gram-positive (MDRP) | 19(5) | 4(1) | 6(2) | 0 | 0 | 1 | 30(8) |
| | 12 | 2 | 6 | 1 | 21 | ||
| | 10 (6/4) | 2 (1/1) | 6 (4/2) | 1 | 19 (12/7) | ||
| | 1 | 1 | |||||
| | 1 | 1 | |||||
| 6 | 2 | 8 | |||||
| | 4 | 4 | |||||
| | 2 | 2 | |||||
| | 2 | 2 | |||||
| | 1(1) | 1(1) | |||||
| Gram-negative (MDRP) | 11(5) | 14(8) | 7(2) | 2 | 3(2) | 1 | 38(17) |
| | 4(2) | 5(2) | 2 | 2(1) | 1 | 14(5) | |
| | 3(2) | 1 | 3(1) | 1 | 8(3) | ||
| | 1 | 1 | 1 | 3 | |||
| | 1(1) | 3(2) | 1(1) | 1(1) | 6(5) | ||
| | 1 | 1 | 2 | ||||
| | 1 | 1 | |||||
| | 4(4) | 4(4) | |||||
| All MDRP | 10 | 9 | 4 | 0 | 2 | 0 | 25 |
| Fungus | 3 | 6 | 0 | 4 | 3 | 1 | 17 |
| | 3 | 4 | 4 | 1 | 1 | 13 | |
| | 2 | 2 | |||||
| | 2 | 2 | |||||
MDRP Multidrug-resistant pathogen, MRSA Methicillin-resistant Staphylococcus aureus, ESBL Extended spectrum β-lactamases, MDR-PA Multidrug-resistant Pseudomonas aeruginosa, CR-AB Carbapenem-resistant Acinetobacter baumannii, VRE Vancomycin-resistant Enterococcus
Fig. 1Chest CT revealed multiple peripheral nodules with cavitation (arrow, a) and ground-glass opacities (arrowhead, a); peripheral nodules with feeding vessel sign (arrow, b) and a wedge-shaped peripheral lesion (arrowhead, b), consolidation and air bronchogram (arrow, c) and pleural effusion (arrowhead, c)
Fig. 2TTE demonstrated tricuspid valve and right ventricular vegetations (arrow, a); vegetations on the right coronary cusp of the aortic valve (arrow, b); vegetation on the pulmonary valve in a patient with congenital heart disease (arrow, c); and mitral valve vegetations (arrow, d)
Fig. 3Bronchoscopy revealed hyperemia and edema of bronchial mucosa with serous secretion (a) and purulent secretion (b). The cytological examination showed massive PMN cell infiltration in BALF (c). Histopathology examination revealed organizing pneumonia (including widening of alveolar wall, infiltration of inflammatory cells in the lung interstitium, and disappearance of the alveolar cavity with replacement by hyperplastic fibrous tissue; d)
Baseline characteristics by each primary infection of the 98 patients with SPE
| Primary infection foci | Skin and other soft tissue infection | Infective endocarditis | Liver abscess | Catheter-associated blood stream infection | Urinary tract infection | Perianal abscess | Other infection |
|---|---|---|---|---|---|---|---|
| Age, years§ | 49.1 ± 17.0 | 38.8 ± 14.2 | 46.8 ± 13.3 | 52.2 ± 14.3 | 51.0 ± 8.0 | 52.5 ± 10.4 | 46.2 ± 18.0 |
| Pathogens* | |||||||
| Gram-positive | 16 | 8 | 2 | 2 | 1 | 0 | 1 |
| Gram-negative | 14 | 2 | 12 | 3 | 4 | 2 | 1 |
| Fungus | 6 | 2 | 1 | 3 | 5 | 0 | 0 |
| MDRP** | 11 | 2 | 6 | 4 | 0 | 2 | 0 |
| Predisposing conditions | |||||||
| Diabetes mellitus** | 14 | 8 | 9 | 3 | 3 | 1 | 3 |
| Nosocomial infection | 7 | 3 | 3 | 4 | 2 | 1 | 1 |
| IV drug use | 4 | 6 | 3 | 2 | 1 | 2 | 0 |
| Immunosuppressed state | 5 | 3 | 3 | 2 | 2 | 1 | |
| Injury or other trauma | 4 | 2 | 2 | 1 | 1 | 1 | 1 |
| Antimicrobial therapy | |||||||
| Cephalosporin | 17 | 10 | 7 | 2 | 1 | 2 | 4 |
| Vancomycin | 19 | 11 | 0 | 6 | 1 | 0 | 2 |
| Carbapenem | 6 | 5 | 4 | 4 | 1 | 1 | 2 |
| Piperacillin-tazobactam | 4 | 4 | 6 | 1 | 2 | 1 | 2 |
| Aminoglycosides | 0 | 0 | 10 | 1 | 4 | 4 | 0 |
| Quinolones | 2 | 2 | 2 | 0 | 4 | 0 | 2 |
| Antifungal therapy | 8 | 4 | 2 | 4 | 5 | 0 | 3 |
| Drainage | 7 | 14 | 1 | 2 | 2 | 0 | |
| Death | 6 | 4 | 3 | 3 | 1 | 1 | 1 |
| Duration of hospitalization, days§ | 23.4 ± 12.1 | 19.9 ± 9.4 | 22.3 ± 9.4 | 24.1 ± 16.2 | 17.3 ± 6.4 | 32.1 ± 11.0 | 20.8 ± 6.0 |
§There are no significant relationship between age as well as duration of hospitalization and different primary infection of SPE patients, P > 0.05
* There is relationship between pathogens and different primary infection sites of the SPE patients, P < 0.05
** There is no relationship between MDRP as well as diabetes and the different primary infection of SPE patients, P > 0.05
MDRP Multidrug-resistant pathogen